Document Detail


Apolipoprotein E phenotypes in hemodialysis patients.
MedLine Citation:
PMID:  10412789     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Apolipoprotein (apo) E polymorphism consists of three major isoproteins (E2, E3, and E4). Because of their difference in a lipid-modulating effect, the polymorphism has been reported to affect the morbidity of atherosclerosis in general population. Therefore, in hemodialysis (HD) patients, the apo E polymorphism may also modulate serum levels of cholesterol and susceptibility to atherosclerotic vascular disease. METHODS: We determined apo E phenotypes in 493 HD patients and 422 controls. We also investigated vascular risk profile and measured postprandial serum levels of lipids and apos in the dialysis patients. RESULTS: We found a similar phenotype distribution and allele frequency between HD patients and healthy controls. Serum levels of total cholesterol, triglyceride, and apo A I, A II, and C III did not differ significantly among patients with phenotypes apo E2/3, E3/3, and E3/4. Patients with apo E3/4 had significantly lower levels of high-density lipoprotein cholesterol, significantly higher levels of low-density lipoprotein cholesterol (LDL-C), and a higher atherogenic index than those with apo E2/3 (LDL-C, 100 +/- 30 vs. 82 +/- 35 mg/dl, P < 0.01; the index, 3.3 +/- 1.7 vs. 2.3 +/- 1.3, P < 0.01). Patients with apo E3/4 showed a tendency toward higher levels of apo B than patients with apo E2/3 or apo E3/3. Multiple logistic regression analysis revealed that age and diabetes mellitus, but not apo E phenotypes, were independent risk factors for vascular disease. CONCLUSIONS: Apo E polymorphism modulates cholesterol metabolism in dialysis patients but appears to have little association with the prevalence of atherosclerotic complications in the patients.
Authors:
T Imura; H Kimura; F Gejyo
Related Documents :
22249209 - Association of cd20 levels with clinicopathological parameters and its prognostic signi...
22696589 - Large clones with pnh type phenotype are not common in patients presenting with intra-a...
16809559 - Statin treatment is not associated with consistent alterations in inflammatory status o...
22505379 - Potential proteomic biomarkers in assessing liver fibrosis using seldi-tof ms.
21670399 - Clinical correlates of white matter tract degeneration in progressive supranuclear palsy.
22763619 - Anterior cingulate glutamate levels related to clinical status following treatment in f...
25318789 - Cognitive and affective assessments of multiple sclerosis (ms) and neuromyelitis optica...
24582759 - Elevated melatonin levels in natalizumab-treated female patients with relapsing-remitti...
19309299 - Sporadic and men1-related primary hyperparathyroidism: differences in clinical expressi...
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Kidney international. Supplement     Volume:  71     ISSN:  0098-6577     ISO Abbreviation:  Kidney Int. Suppl.     Publication Date:  1999 Jul 
Date Detail:
Created Date:  1999-09-15     Completed Date:  1999-09-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7508622     Medline TA:  Kidney Int Suppl     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S245-7     Citation Subset:  IM    
Affiliation:
Department of Clinical and Laboratory Medicine, Faculty of Medicine, Fukui Medical University, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Aged
Alleles
Apolipoproteins E / genetics*
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Diabetes Complications
Female
Gene Frequency
Humans
Male
Middle Aged
Phenotype
Regression Analysis
Renal Dialysis*
Risk Factors
Vascular Diseases / blood,  complications
Chemical
Reg. No./Substance:
0/Apolipoproteins E; 0/Cholesterol, HDL; 0/Cholesterol, LDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients.
Next Document:  Abnormalities in lipoprotein metabolism in hemodialysis patients.